ESR1 and breast carcinoma: For example, inhibition of hyperactive MAPK by U0126, a MAPK/ERK kinase1/2 inhibitor, resulted in restoration of ERα mRNA and protein in ERα (-) breast cancer cells and conferred their sensitivity to the antiestrogen agents tamoxifen and faslodex 18, 19.